Affordable Access

Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma

Authors
Journal
Gynecologic Oncology
0090-8258
Publisher
Elsevier
Publication Date
Volume
104
Issue
3
Identifiers
DOI: 10.1016/j.ygyno.2006.09.006
Keywords
  • Gemcitabine
  • Cisplatin
  • Chemotherapy
  • Refractory
  • Resistant
  • Ovarian Cancer
Disciplines
  • Medicine

Abstract

Abstract Objectives. Synergism between gemcitabine and cisplatin is supported by preclinical and clinical data. The present study explores the efficacy of a biweekly regimen in platinum-resistant/refractory, paclitaxel-pretreated ovarian and peritoneal cancer. Methods. 50 paclitaxel-pretreated patients with platinum-resistant/refractory ovarian or peritoneal carcinoma who had previously received paclitaxel chemotherapy, were treated with six cycles of gemcitabine 1000 mg/m 2 followed by cisplatin 40 mg/m 2 on days 1 and 15, repeated every 4 weeks. Results. The median platinum-free interval (PFI) was 4 months while the median number of previous treatment lines was 2. Chemotherapy was well tolerated. Objective responses were observed in 31.5% of evaluable patients ( n = 35). CA125 response was observed in 68% of patients with elevated CA125 ( n = 41). Median overall survival (OS) was 13.2 months (95% Confidence Interval, CI: 10.2–16.2) while progression-free survival (PFS) was 4.9 months (95%CI: 3.5–6.4). A PFI of less than 3 months was associated with lower objective response rates (15.8% versus 50%, p = 0.03). Conclusions. Biweekly gemcitabine and cisplatin is feasible for patients with platinum-resistant ovarian or peritoneal cancer and is associated with a favorable toxicity profile. In a population with recent exposure to platinum, a PFI of less than 3 months was the major factor influencing response to chemotherapy.

There are no comments yet on this publication. Be the first to share your thoughts.